Regine Heilbronn, until 2020 Director of the Institute of Virology at Charité has since transitioned as head of the GO-Bio team and founding CEO of EpiBlok Therapeutics GmbH in Berlin. She looks back to over 20 years of research on AAV virology and vector technology starting with Harald zur Hausen in Heidelberg, then as group leader at the Max-Planck-Institute for Biochemistry in Martinsried, before being appointed as Full Professor of Experimental and Clinical Virology at the Free University of Berlin. She filed a series of patent applications on AAV-based gene therapy including a scalable AAV production system assigned to AGCT, Fl. where she holds equity.
Prof. Heilbronn studied medicine in Düsseldorf, Glasgow, UK, and Freiburg where she gained her M.D. in biochemistry, and in 2020 an Executive MBA from the European School of Management and Technology (ESMT) in Berlin.